Novo Nordisk, the Danish pharmaceutical organization recognised for its blockbuster weight loss pills Wegovy and Ozempic, has filed a lawsuit in opposition to telehealth issuer Hims & Hers after the American organization released a $forty nine compounded weight loss tablet mimicking its medications. The felony motion, filed in U.S. District Court in Delaware, accuses Hims & Hers of patent infringement and promoting cheaper, unapproved variations of Wegovy, which includes the lively aspect semaglutide.
The circulate through Hims & Hers closing week to introduce its compounded semaglutide tablet prompted significant backlash from each Novo Nordisk and U.S. regulators. The Food and Drug Administration (FDA) stepped in, caution Hims & Hers and different compounding pharmacies approximately advertising non-FDA-authorized variations of GLP-1 pills like semaglutide, elevating worries approximately quality, protection, and efficacy. The Department of Health and Human Services additionally referred Hims & Hers to the Department of Justice for capability research into violations of federal drug laws.
Under multiplied felony and regulatory pressure, Hims & Hers introduced over the weekend it might halt income of its compounded weight loss tablet. The organization said on social media that it made the selection after keeping discussions with enterprise stakeholders and reiterated its dedication to offering secure and low-cost care. Despite the withdrawal, Novo Nordisk keeps to allege that Hims & Hers is unlawfully compounding and selling each tablet and injectable variations of its FDA-authorized pills, setting affected person protection at risk.
Mass compounding of medication like Wegovy have become not unusualplace all through shortages of GLP-1 weight loss and diabetes medications, however the FDA ended allowances for such practices after asserting the shortages over. The regulator has seeing that pledged to limition the usage of GLP-1 lively elements in unapproved compounded remedies and warned that agencies discovered violating those policies should face felony motion with out in addition notice.
Financial markets reacted speedy to the unfolding situation. Shares of Hims & Hers dropped sharply on Monday morning, at the same time as Novo Nordisk’s inventory fee rebounded following information of the lawsuit and the telehealth issuer’s selection to tug the contested tablet. The ongoing dispute highlights the acute opposition and regulatory scrutiny withinside the hastily developing weight loss drug market.
